ELVN-002
Phase 1Small molecule
ELVN-002 is one of 67 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
66
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Adenocard
AstellasPreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Vfend
PPrism Pharmaceuticals
Preclinical
ELVN-002
EEnliven Therapeutics
Phase 1
Tianeptine
PfizerPreclinical
Ablavar
LLantheus Medical Imaging
Preclinical
Diuretic
RReprieve Cardiovascular, Inc
Preclinical
Recombinant Human Endostatin
PPeking University Third Hospital
Preclinical
Tc99m Sestamibi
MM.D. Anderson Cancer Center
Preclinical
Liposomal Irinotecan and Apatinib
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ELVN-002. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- EEnliven Therapeutics